Design of peptide and peptidomimetic ligands with novel pharmacological activity profiles

Annual Review of Pharmacology and Toxicology

Volumn 53, Issue , 2013, Pages 557-580

  Hruby, Victor J ^a   Cai, Minying ^a  

^a University of Arizona   (United States)

Author keywords

blood brain barrier; conformation and biological activity; peptide hormones; peptide neurotransmitters; peptide pharmacophores; peptide stability; topographical structures

Indexed keywords

4 [ALPHA (4 ALLYL 2,5 DIMETHYL 1 PIPERAZINYL) 3 HYDROXYBENZYL] N,N DIETHYLBENZAMIDE; ALPHA INTERMEDIN; BETA METHYL 2',6' DIMETHYLTYROSINE; DELTORPHIN; ENKEPHALIN; GLUCAGON DERIVATIVE; MELANOCORTIN; MELANOTAN II; N ACETYL ALPHA INTERMEDIN[4-10]CYCLO[4 NORLEUCINE 5 ASPARTIC ACID 7 [3 (2 NAPHTHYL)ALANINE] 10 LYSINAMIDE]; NEUROKININ 1 RECEPTOR ANTAGONIST; NEUROTRANSMITTER; PENICILLAMINE; PEPTIDE DERIVATIVE; PEPTIDE HORMONE; PEPTIDOMIMETIC AGENT; SOMATOSTATIN DERIVATIVE; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; BINDING AFFINITY; BIOLOGICAL ACTIVITY; BLOOD BRAIN BARRIER; DIABETES MELLITUS; DRUG DESIGN; GLUCOSE HOMEOSTASIS; HUMAN; NEUROPATHIC PAIN; NONHUMAN; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; PROTEIN CONFORMATION; REVIEW; STRUCTURE ACTIVITY RELATION;

ANIMALS; BLOOD-BRAIN BARRIER; DRUG DESIGN; HUMANS; LIGANDS; PEPTIDES; PEPTIDOMIMETICS;

EID: 84872260755     PISSN: 03621642     EISSN: 15454304     Source Type: Book Series    
DOI: 10.1146/annurev-pharmtox-010510-100456     Document Type: Review

References (108)

1. Hruby VJ. 2009. Organic chemistry and biology: chemical biology through the eyes of collaboration. J. Org. Chem. 74:9245-64
2. Hruby VJ. 1982. Conformational restrictions of biologically active peptides via amino acid side chain groups. Life Sci. 31:189-99
3. Kessler H. 1982. Conformational and biological activity of cyclic peptides. Angew. Chem. Int. Ed. Engl. 21:512-23
4. Ferrier BM, Jarvis D, du Vigneaud V. 1965. Deamino-oxytocin: its isolation by partition chromatography on Sephadex and crystallization from water, and its biological activities. J. Biol. Chem. 240:4264-66
5. Rudinger J. 1971. The design of peptide hormone analogs. In Drug Design,Vol. 2, ed. EJ Ariens, pp. 319-419. New York: Academic
6. Hruby VJ. 2002. Designing peptide receptor agonists and antagonists. Nat. Rev. Drug Discov. 1:847-58
7. Lipinski CA, Lombardo F, Dominy BW, Feeney PJ. 1997. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug Deliv. Rev. 23:3-25
8. Kastin AJ, Nissen C, Nikolics K, Medzihradszky K, Coy DH, et al. 1996. Distribution of 3H-α-MSH in rat brain. Brain Res. Bull. 1(1):19-26
9. Pan W, Tu H, Kastin AJ. 2006. Differential BBB interactions of three ingestive peptides: obestatin, ghrelin, and adiponectin. Peptides 27:911-16
10. Witt KA, Gillespie TJ, Huber JD, Egleton RD, Davis TP. 2001. Peptide drug modifications to enhance bioavailability and blood-brain barrier permeability. Peptides 22:2329-43
11. Egleton RD, Davis TP. 2005. Development of neuropeptide drugs that cross the blood-brain barrier. NeuroRx 2:44-53
12. Abbruscato TJ, Williams SA, Misicka A, Lipkowski AW, Hruby VJ, Davis TP. 1996. Blood-to-central nervous system entry and stability of biphalin, a unique double-enkephalin analog, and its halogenated derivatives. J. Pharmacol. Exp. Ther. 276:1049-57
13. Egleton RD, Mitchell SA, Huber JD, Palian MM, Polt R, Davis TP. 2001. Improved blood-brain barrier penetration and enhanced analgesia of an opioid peptide by glycosylation. J. Pharmacol. Exp. Ther. 299:967-72
14. Davis TP, Abbruscato TJ, Brownson E, Hruby VJ. 1995. Conformationally constrained peptide drugs targeted at the blood-brain barrier. In Membranes and Barriers: Targeted Drug Delivery, ed. RS Rapaka, NIDA Res. Monogr. 154:47-60. Washington, DC: Natl. Inst. Drug Abuse
15. Sharma SD, Nikiforovich GV, Jiang J, de Lauro Castrucci AM,Hadley ME, Hruby VJ. 1994. Cationized melanotropin analogues: structure function relationships. In Peptides: Chemistry, Structure and Biology, ed. RS Hodges, JA Smith, pp. 398-399. Leiden, Neth.: ESCOM
16. Sharma SD, Nikiforovich GV, Jiang J, de Lauro Castrucci AM, Hadley ME, Hruby VJ. 1993. A new class of positively charged melanotropin analogs: a new concept in peptide design. In Peptides 1992, ed. CH Schneider, AN Eberle, pp. 95-96. Leiden, Neth.: ESCOM
17. Wakelam MJO, Murphy GJ, Hruby VJ, Houslay MD. 1986. Activation of two signal-transduction systems in hepatocytes by glucagon. Nature 323:68-71
18. Kenakin T. 2007. Allosteric theory: taking therapeutic advantage of the malleable nature of GPCRs. Curr. Neuropharmacol. 5:149-56
19. Conn PJ, Christopoulos A, Lindsley CW. 2009. Allosteric modulators of GPCRs: a novel approach for the treatment of CNS disorders. Nat. Rev. Drug Discov. 8(1):41-54
20. Lewis JA, Lebois EP, LindsleyCW.2008. Allosteric modulation of kinases andGPCRs: design principles and structure diversity. Curr. Opin. Chem. Biol. 12(3):269-80
21. May LT, Leach K, Sexton PM, Christopoulos A. 2007. Allosteric modulation of G protein-coupled receptors. Annu. Rev. Pharmacol. Toxicol. 47:1-51
22. Hruby VJ, al-Obeidi F, Kazmierski WM. 1990. Emerging approaches in the molecular design of receptor-selective peptide ligands: conformational, topographical and dynamic considerations. Biochem. J. 268:249-62
23. Hruby VJ. 1993. Conformational and topographical considerations in the design of biologically active peptides. Biopolymers 33:1073-82
24. Hruby VJ, Li G, Haskell-Luevano C, Shenderovich MD. 1997. Design of peptides, proteins, and peptidomimetics in chi space. Biopolymers 43:219-66
25. Gibson SE, Guillo N, Tozer MJ. 1999. Towards control of χ-space: conformationally constrained analogues of Phe, Tyr, Trp and His. Tetrahedron 55:585-615
26. Hruby VJ. 2001. Design in topographical space of peptide and peptidomimetic ligands that affect behavior. A chemist's glimpse at the mind-body problem. Acc. Chem. Res. 34:389-97
27. Hruby VJ, Gehrig CA. 1989. Recent developments in the design of receptor specific opioid peptides. Med. Res. Rev. 9:343-401
28. GacelG,Zajac JM,Delay-Goyet P, DauǵeV,RoquesBP. 1988. Investigation of the structural parameters involved in the μ and δ opioid receptor discrimination of linear enkephalin-related peptides. J. Med. Chem. 31:374-83
29. Mosberg HI, Hurst R, Hruby VJ, Gee K, Yamamura HI, et al. 1983. Bis-penicillamine enkephalins possess highly improved specificity toward δ opioid receptors. Proc. Natl. Acad. Sci. USA 80:5871-74
30. Ramachandran GN, Sasisekharan V. 1968. Conformation of polypeptides and proteins. Adv. Protein Chem. 23:283-437
31. Akiyama K, Gee KW, Mosberg HI, Hruby VJ, Yamamura HI. 1985. Characterization of [3H][2-D-penicillamine,5-D-penicillamine]-enkephalin binding to δ opiate receptors in the rat brain and neuroblastoma-glioma hybrid cell line (NG 108-15). Proc. Natl. Acad. Sci. USA 82:2543-47
32. Hruby VJ, Kao LF, Pettitt BM, Karplus M. 1988. The conformational properties of the delta opioid peptide [D-Pen2, D-Pen5]enkephalin in aqueous solution determined by NMR and energy minimization calculations. J. Am. Chem. Soc. 110:3351-59
33. Flippen-Anderson JL, Hruby VJ, Collins N, George C, Cudney B. 1994. X-ray structure of [D-Pen2, D-Pen5]enkephalin, a highly potent, δopioid receptor-selective compound: comparisons with proposed solution conformations. J. Am. Chem. Soc. 116:7523-31
34. Weber SJ, Greene DL, Sharma SD, Yamamura HI, Kramer TH, et al. 1991. Distribution and analgesia of [3H][D-Pen2, D-Pen5]enkephalin and two halogenated analogues after intravenous administration. J. Pharmacol. Exp. Ther. 259:1109-17
35. Williams SA, Abbruscato TJ, Hruby VJ, Davis TP. 1996. Passage of a δ-opioid receptor selective enkephalin, [D-penicillamine2,5]enkephalin, across the blood-brain and the blood-cerebrospinal fluid barriers. J. Neurochem. 66:1289-99
36. Hruby VJ, T́ oth G, Gehrig CA, Kao LF, Knapp R, et al. 1991. Topographically designed analogues of [D-Pen2, D-Pen5]enkephalin. J. Med. Chem. 34:1823-30
37. Qian X, Russell KC, Boteju LW, Hruby VJ. 1995. Stereoselective total synthesis of topographically constrained designer amino acids: 2-, 6-dimethyl-β-methyltyrosines. Tetrahedron 51:1033-54
38. Qian X, Shenderovich MD, K̈ ov́er KE, Davis P, Horv́ath R, et al. 1996. Probing the stereochemical requirements for receptor recognition of δopioid agonists through topographicmodifications in position 1. J. Am. Chem. Soc. 118:280-90
39. Bilsky EJ, Qian X, Hruby VJ, Porreca F. 2000. Antinociceptive activity of [β-methyl-2-,6-dimethyltyrosine1]-substituted cyclic[ D-Pen2, D-Pen5]enkephalin and [D-Ala2,Asp4]deltorphin analogs. J. Pharmacol. Exp. Ther. 293:151-58
40. Okura T, Cowell SM, Varga E, Burkey TH, Roeske WR, et al. 2000. Differential down-regulation of the human δ-opioid receptor by SNC80 and [D-Pen2, D-Pen5]enkephalin. Eur. J. Pharmacol. 387:R11-13
41. Schiller PW, Nguyen TM-D,Weltrowska G,Wilkes BC, Marsden BJ, et al. 1992. Differential stereochemical requirements of μ versus δ opioid receptors for ligand binding and signal transduction: development of a class of potent and highly δ-selective peptide antagonists. Proc. Natl. Acad. Sci. USA 89:11871-75
42. Salvadori S, Attila M, Balboni G, Bianchi C, Bryant SD, et al. 1995. δ opioidmimetic antagonists: prototypes for designing a new generation of ultraselective opioid peptides. Mol. Med. 1(6):678-89
43. Liao S, Lin J, Shenderovich MD, Han Y, Hosohata K, et al. 1997. The stereochemical requirements of the novel δ-opioid selective dipeptide antagonist TMT-Tic. Bioorg. Med. Chem. Lett. 7:3049-52
44. Hosohata K, Burkey TH, Alfaro-Lopez J, Hruby VJ, Roeske WR, Yamamura HI. 1999. (2S,3R)TMTL-Tic-OH is a potent inverse agonist at the human δ-opioid receptor. Eur. J. Pharmacol. 380:R9-10
45. Hosohata K, Varga EV, Alfaro-Lopez J, Tang X, Vanderah TW, et al. 2003. (2S,3R)β-Methyl-2-,6-dimethyltyrosine-L-tetrahydroisoquinoline-3- carboxylic acid [(2S,3R)TMT-L-Tic-OH] is a potent, selective δ-opioid receptor antagonist in mouse brain. J. Pharmacol. Exp. Ther. 304:683-88
46. Liao S, Alfaro-Lopez J, Shenderovich MD, Hosohata K, Lin J, et al. 1998. De novo design, synthesis, and biological activities of high-affinity and selective non-peptide agonists of the δ-opioid receptor. J. Med. Chem. 41:4767-76
47. Knapp RJ, Santoro G, De Leon IA, Lee KB, Edsall SA, et al. 1996. Structure-activity relationships for SNC80 and related compounds at cloned δand μopioid receptors. J. Pharmacol. Exp. Ther. 277:1284-91
48. Hosohata Y, Varga EV, Stropova D, Li X, Knapp RJ, et al. 2001. Mutation W284L of the human δ opioid receptor reveals agonist specific conformational mechanisms of G protein activation. Life Sci. 68:2233-42
49. Li X, Knapp RJ, Stropova D, Varga E, Wang Y, et al. 1995. Trp284 of the human δ opioid receptor is required for SNC121 binding but not binding of pCl-DPDPE, deltorphin II or naltrindole. Analgesia 1:539-42
50. Liao S, Shenderovich MD, Zhang Z, Maletinska L, Slaninova J,Hruby VJ. 1998. Substitution of the sidechain-constrained amino acids β-methyl-2-,6- dimethyl-4-methoxytyrosine in position 2 of a bicyclic oxytocin analogue provides unique insights into the bioactive topography of oxytocin antagonists. J. Am. Chem. Soc. 120:7393-94
51. Rezik M, Havlicek V, Leybin L, LaBella FS, Friesen H. 1978. Opiate-like naloxone-reversible actions of somatostatin given intracerebrally. Can. J. Physiol. Pharmacol. 56:227-31
52. Veber DF, Holly FW, Nutt RF, Bergstrand SJ, Brady SF, et al. 1979. Highly active cyclic and bicyclic somatostatin analogues of reduced ring size. Nature 280:512-14
53. Maurer R, Gaehwiler BH, Buescher HH, Hill RC, Roemer D. 1982. Opiate antagonistic properties of an octapeptide somatostatin analog. Proc. Natl. Acad. Sci. USA 79:4815-17
54. Pelton JT, Gulya K, Hruby VJ, Duckles SP, Yamamura HI. 1985. Conformationally restricted analogs of somatostatin with high μ-opiate receptor specificity. Proc. Natl. Acad. Sci. USA 82:236-39
55. Kazmierski WM,Wire WS, Lui GK, Knapp RJ, Shook JE, et al. 1988. Design and synthesis of somatostatin analogues with topographical properties that lead to highly potent and specific μopioid receptor antagonists with greatly reduced binding at somatostatin receptors. J. Med. Chem. 31:2170-77
56. Hawkins KN, Knapp RJ, Lui GK, Gulya K, Kazmierski WM, et al. 1989. [3H]-[H-D-Phe-Cys-Tyr-DTrp-Orn-Thr-Pen-Thr-NH2] ([3H]CTOP), a potent and highly selective peptide forμopioid receptors in rat brain. J. Pharmacol. Exp. Ther. 248:73-80
57. Dorr RT, Lines R, Levine N, Brooks C, Xiang L, et al. 1996. Evaluation ofMelanotan-II, a superpotent cyclic melanotropic peptide in a pilot phase-I clinical study. Life Sci. 58:1777-84
58. Hadley ME, Hruby VJ, Blanchard J, Dorr RT, Levine N, et al. 1998. Discovery and development of novel melanogenic drugs,Melanotan-I and-II. In Integration of Pharmaceutical Discovery and Development: Case Histories, ed. R Borchardt, RM Freidinger, TK Sawyer, pp. 575-95. New York: Plenum
59. Wessells H, Gralnek D, Dorr R, Hruby VJ, Hadley ME, Levine N. 2000. Effect of an alpha-melanocyte stimulating hormone analog on penile erection and sexual desire inmen with organic erectile dysfunction. Urology 56:641-46
60. Dorr RT, Dvorakova K, Brooks C, Lines R, Levine N, et al. 2000. Increased eumelanin expression and tanning is induced by a superpotent melanotropin [Nle4-D-Phe7]α-MSH in humans. Photochem. Photobiol. 72:526-32
61. Engel MH, Sawyer TK, Hadley ME, Hruby VJ. 1981. Quantitative determination of amino acid racemization in heat-alkali-treated melanotropins: implications for peptide hormone structure-function studies. Anal. Biochem. 116:303-11
62. Sawyer TK, Sanfilippo PJ, Hruby VJ, Engel MH, Heward CB, et al. 1980. 4-Norleucine, 7-Dphenylalanine-α-melanocyte-stimulating hormone: a highly potent α-melanotropin with ultralong biological activity. Proc. Natl. Acad. Sci. USA 77:5754-58
63. Hadley ME, Anderson B, Heward CB, Sawyer TK, Hruby VJ. 1981. Calcium-dependent prolonged effects on melanophores of [4-norleucine, 7-D-phenylalanine]-α-melanotropin. Science 213:1025-27
64. de Lauro Castrucci AM, Hadley ME, Sawyer TK, Hruby VJ. 1984. Enzymological studies of melanotropins. Comp. Biochem. Physiol. B 78:519-24
65. Sawyer TK, Hruby VJ, Darman PS, Hadley ME. 1982. [half-Cys4,half-Cys10]- α-melanocytestimulating hormone: a cyclic α-melanotropin exhibiting superagonist biological activity. Proc. Natl. Acad. Sci. USA 79:1751-55
66. Hruby VJ, Wilkes BC, Cody WL, Sawyer TK, Hadley ME. 1984. Melanotropins: structural, conformational, and biological considerations in the development of superpotent and superprolonged analogs. Pept. Protein Rev. 3:1-64
67. al-Obeidi F, Hadley ME, Pettitt BM, Hruby VJ. 1989. Design of a new class of superpotent cyclic α-melanotropins based on quenched dynamic simulations. J. Am. Chem. Soc. 111:3413-16
68. Hruby VJ, Lu D, Sharma SD, de Lauro Castrucci AM, Kesterson RA, et al. 1995. Cyclic lactam α-melanotropin analogues of Ac-Nle4-cyclo[Asp5, D-Phe7,Lys10]α-melanocyte-stimulating hormone-(4-10)-NH2 with bulky aromatic amino acids at position 7 show high antagonist potency and selectivity at specific melanocortin receptors. J. Med. Chem. 38:3454-61
69. Grieco P, Balse PM, Weinberg D, MacNeil T, Hruby VJ. 2000. D-amino acid scan of γ-melanocytestimulating hormone: importance of Trp8 on human MC3 receptor selectivity. J. Med. Chem. 43:4998-5002
70. Cai M, Cai C, Mayorov AV, Xiong C, Cabello CM, et al. 2004. Biological and conformational study of β-substituted prolines in MT-II template: steric effects leading to human MC5 receptor selectivity. J. Pept. Res. 63:116-31
71. Ballet S, Mayorov AV, Cai M, Tymecka D, Chandler KB, et al. 2007. Novel selective human melanocortin-3 receptor ligands: use of the 4-amino-1,2,4,5- tetrahydro-2-benzazepin-3-one (Aba) scaffold. Bioorg. Med. Chem. Lett. 17:2492-98
72. Bednarek MA,MacNeilT,Tang R, Fong TM, Cabello MA, et al. 2008. Cyclic analogs ofα-melanocytestimulating hormone (αMSH) with high agonist potency and selectivity at humanmelanocortin receptor 1b. Peptides 29:1010-17
73. Hruby VJ, Cai M, Cain JP,Mayorov AV, Dedek MM, Trivedi D. 2007. Design, synthesis and biological evaluation of ligands selective for the melanocortin-3 receptor. Curr. Top. Med. Chem. 7:1085-97
74. CaiM,Nyberg J, Hruby VJ. 2009. Melanotropins as drugs for the treatment of obesity and other feeding disorders: potential and problems. Curr. Top. Med. Chem. 9:554-63
75. Doedens L, Opperer F, Cai M, Beck JG, Dedek M, et al. 2010. Multiple N-methylation of MT-II backbone amide bonds leads to melanocortin receptor subtype hMC1R selectivity: pharmacological and conformational studies. J. Am. Chem. Soc. 132(23):8115-28
76. Cain JP,Mayorov AV, Cai M, Wang H, Tan B, et al. 2006. Design, synthesis, and biological evaluation of a new class of small molecule peptide mimetics targeting the melanocortin receptors. Bioorg. Med. Chem. Lett. 16:5462-67
77. Wessells H, Fuciarelli K, Hansen J, Hadley ME, Hruby VJ, et al. 1998. Synthetic melanotropic peptide initiates erections in men with psychogenic erectile dysfunction: double-blind, placebo controlled crossover study. J. Urol. 160:389-93
78. Kahn CR,Weir GC, eds. 1994. Joslin's Diabetes Mellitus. Philadelphia: LippincottWilliams & Wilkins. 1068 pp. 13th ed.
79. Hruby VJ, Wright DE, Lin MC, Rodbell M. 1976. Semisynthetic glucagon derivatives for structurefunction studies. Metabolism 25:1323-25
80. Wright DE, Hruby VJ, Rodbell M. 1978. A reassessment of structure-function relationships in glucagon: glucagon1?21 is a full agonist. J. Biol. Chem. 253:6338-40
81. Bregman MD, Hruby VJ. 1979. Synthesis and isolation of a glucagon antagonist. FEBS Lett. 101:191-94
82. Johnson DG, Goebel CU, Hruby VJ, Bregman MD, Trivedi DB. 1982. Hyperglycemia of diabetic rats decreased by a glucagon receptor antagonist. Science 215:1115-16
83. McKee RL, Pelton JT, Trivedi D, Hruby VJ, Sueiras-Diaz J, Coy DH. 1986. Receptor binding and adenylate cyclase activities of glucagon analogs modified in the N-terminal region. Biochemistry 25:1650-56
84. Krstenansky JL, Trivedi D, Hruby VJ. 1986. Importance of the 10-13 region of glucagon for its receptor interactions and activation of adenylate cyclase. Biochemistry 25:3833-39
85. Hruby VJ, Krstenansky J, Gysin B, Pelton JT, Trivedi D,McKee RL. 1986. Conformational considerations in the design of glucagon agonists and antagonists: examination using synthetic analogs. Biopolymers 25:S135-55
86. Murphy GJ, Hruby VJ, Trivedi D, Wakelam MJO, Houslay MD. 1987. The rapid desensitization of glucagon-stimulated adenylate cyclase is a cyclic AMP-independent process that can be mimicked by hormones which stimulate inositol phospholipid metabolism. Biochem. J. 243:39-46
87. Grady T, Fickova M, Tager HS, Trivedi D, Hruby VJ. 1987. Stimulation and inhibition of cAMP accumulation by glucagon in canine hepatocytes. J. Biol. Chem. 262:15514-20
88. Azizeh BY, Van Tine BA, Sturm NS, Hutzler AM, David C, et al. 1995. [des His1,des Phe6,Glu9]glucagon amide: a newly designed "pure" glucagon antagonist. Bioorg. Med. Chem. Lett. 5:1849-52
89. Azizeh BY, Van Tine BA, Trivedi D, Hruby VJ. 1997. Pure glucagon antagonists: biological activities and cAMP accumulation using phosphodiesterase inhibitors. Peptides 18:633-41
90. Hruby VJ, Ahn JM, Trivedi D. 2001. The design and biological activities of glucagon agonists and antagonists, and their use in examining the mechanisms of glucose action. Curr. Med. Chem. Immunol. Endocr. Metab. Agents 1:199-215
91. King T, Ossipov MH, Vanderah TW, Porreca F, Lai J. 2005. Is paradoxical pain induced by sustained opioid exposure in underlying mechanism of opioid antinociceptive tolerance? Neurosignals 14:194-205
92. Hruby VJ, Porreca F, Yamamura HI, Tollin G, Agnes RS, et al. 2006. New paradigms and tools in drug design for pain and addiction. AAPS J. 8(3):E450-60
93. King T, Gardella LR,Wang R, Vandanyan A, Ossipov MH, et al. 2005. Role of NK-1 neurotransmission on opioid-induced hyperalgesia. Pain 116(3):276-88
94. Gu G, Kondo I, Hua XY, Yaksh TL. 2005. Resting and evoked spinal substance P release during chronic intrathecal morphine infusion: parallels with tolerance and dependence. J. Pharmacol. Exp. Ther. 314(3):1362-69
95. Powell KJ, Quirion R, Jhamandas K. 2003. Inhibition of neurokinin-1-substance P receptor and prostanoid activity prevents and reverses the development of morphine tolerance in vivo and the morphine-induced increase in CGRP expression in cultured dorsal root ganglion neurons. Euro J. Neurosci. 18(6):1572-83
96. Yamamoto T, Nair P, Vagner J, Largent-Milnes T, Davis P, et al. 2008. A structure-activity relationship study and combinatorial synthetic approach of C-terminal modified bifunctional peptides that are δ/μ opioid receptor agonists and neurokinin 1 receptor antagonists. J. Med. Chem. 51:1369-76
97. Yamamoto T, Nair P, Jacobsen NE,Davis P,Ma SW, et al. 2008. The importance ofmicelle-bound states for the bioactivities of bifunctional peptide derivatives for δ/μopioid receptor agonists and neurokinin-1 receptor antagonists. J. Med. Chem. 51:6334-47
98. Yamamoto T, Nair P, Jacobsen NE, Vagner J, Kulkarni V, et al. 2009. Improving metabolic stability by glycosylation: bifunctional peptide derivatives that are opioid receptor agonists and neurokinin 1 receptor antagonists. J. Med. Chem. 52:5164-75
99. Largent-Milnes TM, Yamamoto T, Nair P, Hruby VJ, Lai J, et al. 2010. Spinal or systemic TY005, a peptidic opioid agonist/neurokinin 1 antagonist, attenuates pain with reduced tolerance.Br. J. Pharmacol. 161:986-1001
100. Agnes RS, Lee YS, Davis P, Ma SW, Badghisi H, et al. 2006. Structure-activity relationships of bifunctional peptides based on overlapping pharmacophores at opioid and cholecystokinin receptors. J. Med. Chem. 49:2868-75
101. Agnes RS, Ying J, K̈ ov́er KE, Lee YS,Davis P, et al. 2008. Structure-activity relationships of bifunctional cyclic disulfide peptides based on overlapping pharmacophores at opioid and cholecystokinin receptors. Peptides 29:1413-23
102. Gillies RJ, Hruby VJ. 2003. Expression-driven reverse engineering of targeted imaging and therapeutic agents. Expert Opin. Ther. Targets 7:137-39
103. Handl HL, Vagner J, Han H, Mash E, Hruby VJ, Gillies RJ. 2004. Hitting multiple targets with multimeric ligands. Expert Opin. Ther. Targets 8:565-86
104. Sharma SD, Jiang J, Hadley ME, Bentley DL, Hruby VJ. 1996. Melanotropic peptide-conjugated beads formicroscopic visualization and characterization ofmelanomamelanotropin receptors. Proc. Natl. Acad. Sci. USA 93:13715-20
105. Vagner J, Xu L, Handl HL, Josan JS, Morse DL, et al. 2008. Heterobivalent ligands crosslink multiple cell-surface receptors: the human melanocortin-4 and δ-opioid receptors. Angew. Chem. Int. Ed. 47:1685-88
106. Josan JS, Morse DL, Xu L, Trissal M, Baggett B, et al. 2009. Solid-phase synthetic strategy and bioevaluation of a labeled δ-opioid receptor ligand Dmt-Tic-Lys for in vivo imaging. Org. Lett. 11(12):2479-82
107. Xu L, Vagner J, Alleti R, Rao V, Jagadish B, et al. 2010. Synthesis and characterization of a Eu-DTPAPEGO-MSH(4) derivative for evaluation of binding of multivalent molecules tomelanocortin receptors. Bioorg. Med. Chem. Lett. 20:2489-92
108. Brabez N, Lynch RM, Xu L, Gillies RJ, Chassaing G, et al. 2011. Design, synthesis, and biological studies of efficient multivalent melanotropin ligands: tools toward melanoma diagnosis and treatment. J. Med. Chem. 54(20):7375-84